Phase I study of the PI3K/mTOR inhibitor PF-05212384 in combination with other antitumor agents.

被引：5
|
作者：
Wainberg, Zev A.
Shapiro, Geoffrey
Curigliano, Giuseppe
Leong, Stephen
Kristeleit, Rebecca Sophie
Maqueda, Maria Alsina
Britten, Carolyn D.
Milella, Michele
Middleton, Mark R.
Olszanski, Anthony J.
Vaishampayan, Ulka N.
Lopez-Martin, Jose A.
Gelmon, Karen A.
Brega, Nicoletta
Pierce, Kristen J.
Perea, Rachelle
Houk, Brett Edward
Pathan, Nuzhat
Gollerkeri, Ashwin
Razak, Albiruni R. A.
机构：
[1] Univ Calif Los Angeles, Med Ctr, Los Angeles, CA 90024 USA
[2] Dana Farber Canc Inst, Boston, MA 02115 USA
[3] Ist Europeo Oncol, Milan, Italy
[4] Univ Colorado, Ctr Canc, Aurora, CO USA
[5] UCL, Inst Canc, London, England
[6] Hosp Valle De Hebron, Barcelona, Spain
[7] Med Univ S Carolina, Charleston, SC 29425 USA
[8] Regina Elena Inst Canc Res, Med Oncol A, Rome, Italy
[9] Oxford NIHR Biomed Res Ctr, Oxford, England
[10] Temple Hlth, Fox Chase Canc Ctr, Philadelphia, PA USA
[11] Wayne State Univ, Karmanos Canc Inst, Detroit, MI USA
[12] Hosp 12 Octubre, E-28041 Madrid, Spain
[13] British Columbia Canc Agcy, Vancouver, BC V5Z 4E6, Canada
[14] Pfizer Italia, Milan, Italy
[15] Pfizer Oncol, Groton, CT USA
[16] Pfizer Worldwide Res & Dev, San Diego, CA USA
[17] Pfizer Inc, Carlsbad, CA USA
[18] Pfizer, San Diego, CA USA
[19] Pfizer BioTherapeut, Cambridge, MA USA
[20] Princess Margaret Canc Ctr, Toronto, ON, Canada
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2015年 / 33卷 / 15期
关键词：
D O I：
10.1200/jco.2015.33.15_suppl.2590
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2590
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Antitumor Efficacy of PKI-587, a Highly Potent Dual PI3K/mTOR Kinase Inhibitor
    Mallon, Robert
    Feldberg, Larry R.
    Lucas, Judy
    Chaudhary, Inder
    Dehnhardt, Christoph
    Delos Santos, Efren
    Chen, Zecheng
    dos Santos, Osvaldo
    Ayral-Kaloustian, Semiramis
    Venkatesan, Aranapakam
    Hollander, Irwin
    CLINICAL CANCER RESEARCH, 2011, 17 (10) : 3193 - 3203
  • [42] A Phase 1B open-label study of gedatolisib (PF-05212384) in combination with other anti-tumour agents for patients with advanced solid tumours and triple-negative breast cancer
    Curigliano, Giuseppe
    Shapiro, Geoffrey, I
    Kristeleit, Rebecca S.
    Razak, Albiruni R. Abdul
    Leong, Stephen
    Alsina, Maria
    Giordano, Antonio
    Gelmon, Karen A.
    Stringer-Reasor, Erica
    Vaishampayan, Ulka N.
    Middleton, Mark
    Olszanski, Anthony J.
    Rugo, Hope S.
    Kern, Kenneth A.
    Pathan, Nuzhat
    Perea, Rachelle
    Pierce, Kristen J.
    Mutka, Sarah C.
    Wainberg, Zev A.
    BRITISH JOURNAL OF CANCER, 2023, 128 (01) : 30 - 41
  • [43] Phase I Safety and Pharmacokinetic Study of the PI3K/mTOR Inhibitor SAR245409 ( XL765) in Combination with Erlotinib in Patients with Advanced Solid Tumors
    Jaenne, Pasi A.
    Cohen, Roger B.
    Laird, A. Douglas
    Mace, Sandrine
    Engelman, Jeffrey A.
    Ruiz-Soto, Rodrigo
    Rockich, Kevin
    Xu, Jianbo
    Shapiro, Geoffrey I.
    Martinez, Pablo
    Felip, Enriqueta
    JOURNAL OF THORACIC ONCOLOGY, 2014, 9 (03) : 316 - 323
  • [44] Apitolisib. Dual PI3K/mTOR inhibitor, Oncolytic
    de Lartigue, Jane
    DRUGS OF THE FUTURE, 2013, 38 (10) : 671 - 678
  • [45] Anti-tumour efficacy of the PI3K inhibitor GDC0941, the dual PI3K/mTOR inhibitor GDC0980 and the MEK inhibitor GDC0973 as single agents and in combination in endometrial carcinomas
    Aslan, O.
    Farrelly, A. M.
    Stordal, B.
    Hennessy, B. T.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S736 - S736
  • [46] PRECLINICAL STUDIES OF THE PI3K/MTOR DUAL INHIBITOR, PF-04691502, IN BREAST CANCER CELL LINES
    Kan, J.
    Yuan, J.
    Lee, N.
    Pavlicek, A.
    Ching, K.
    Cao, J.
    Garza, S.
    Hook, K.
    Christensen, J.
    ANNALS OF ONCOLOGY, 2011, 22 : 55 - 55
  • [47] Preclinical PKPD modeling and human dose projection of PF-046915027, a PI3K/mTOR dual inhibitor
    Luu, Kenneth T.
    Zhang, Eric
    Bagrodia, Shubha
    Yuan, Jing
    CANCER RESEARCH, 2010, 70
  • [48] A novel potent and selective inhibitor of PI3K/mTOR, GDC-0980, currently in phase I clinical trials
    Friedman, Lori S.
    Belvin, Marcia
    Berry, Leanne
    Berry, Megan
    Castanedo, Georgette
    Edgar, Kyle
    Folkes, Adrian
    Guan, Jane
    Heffron, Tim
    Lesnick, John
    Lewis, Cris
    Nonomiya, Jim
    Olivero, Alan
    Patel, Sonal
    Pang, Jodie
    Prior, Wei Wei
    Salphati, Laurent
    Sampath, Deepak
    Sutherlin, Dan
    Wallin, Jeff
    Zhu, Bingyan
    MOLECULAR CANCER THERAPEUTICS, 2009, 8 (12)
  • [49] Antitumor activity of a combination of dual PI3K/mTOR inhibitor SAR245409 and selective MEK1/2 inhibitor pimasertib in endometrial carcinomas
    Inaba, Kanako
    Oda, Katsutoshi
    Ikeda, Yuji
    Sone, Kenbun
    Miyasaka, Aid
    Kashiyama, Tomoko
    Fukuda, Tomohiko
    Uehara, Yuriko
    Arimoto, Takahide
    Kuramoto, Hiroyuki
    Wada-Hiraike, Osamu
    Kawana, Kei
    Yano, Tetsu
    Osuga, Yutaka
    Fujii, Tomoyuki
    GYNECOLOGIC ONCOLOGY, 2015, 138 (02) : 323 - 331
  • [50] Correction to: A Phase 1B open-label study of gedatolisib (PF-05212384) in combination with other anti-tumour agents for patients with advanced solid tumours and triple-negative breast cancer
    Giuseppe Curigliano
    Geoffrey I. Shapiro
    Rebecca S. Kristeleit
    Albiruni R. Abdul Razak
    Stephen Leong
    Maria Alsina
    Antonio Giordano
    Karen A. Gelmon
    Erica Stringer-Reasor
    Ulka N. Vaishampayan
    Mark Middleton
    Anthony J. Olszanski
    Hope S. Rugo
    Kenneth A. Kern
    Nuzhat Pathan
    Rachelle Perea
    Kristen J. Pierce
    Sarah C. Mutka
    Zev A. Wainberg
    British Journal of Cancer, 2023, 128 : 400 - 400
12345